Member Info for trillsg

Forbes, Sky News, Ok Mag to mention just a few. Word's definitely getting out there.
https://www.sciencefocus.com/news/skin-microbiome-beauty-products/

https://twitter.com/gjbrandon/status/1517041971386368000?s=20&t=TRgj3bO6bCAJ3qwjF-uwvw

My pleasure Stu/Gidget. They've always said it would be international and involve the US. Feels like discussions amongst nations has been going on behind the scenes for quite a while and DV are the main topic!

https://www.qeios.com/read/V7S9RR

For those not aware, Mathew produced the recent UK gov presentation, showing MW in their trial. The same guy now now appears to be involved in United States monitoring too. Is he showing them what the UK has and carrying out the same privacy data survey we saw Andrew Engeli do over here?
Review of: "Survey of nationwide public perceptions regarding acceptance of wastewater used for community health monitoring in the United States"
April 2022
DOI:10.32388/V7S9RR
Authors:
Matthew Wade
UK Government
https://www.researchgate.net/publication/360023624_Review_of_Survey_of_nationwide_public_perceptions_regarding_acceptance_of_wastewater_used_for_community_health_monitoring_in_the_United_States

Great update. Lots to look forward to and plenty of Rns's coming in the near future no doubt.

Excellent info T.Rat, keep it flowing bud.

Forbes. Every month, we reach more than 150 million people across all platforms – online, on social, through Live and virtual events, through video and print.

How many are going to read it, like it and want your shares Tuesday? Well done all those that hold!

https://www.forbes.com/sites/davidteich/2022/04/14/machine-learning-for-biology-is-starting-to-move-towards-retail/

I reckon everything is about to come together real soon. The vans, the trials, mass production imminent.

The range of equipment includes Microtox®PD, for real-time detection of SARS-CoV-2 in wastewater treatment plants adding to existing data sampling units installed last year (RNS[ii]: 28th October 2021), extending the trials to April this year.
https://www.lse.co.uk/rns/DVRG/deepverge-q1-production-orders-up-39-to-1635m-y5jreh3py9cdkwe.html

Trotsky. Their last freebie was different to previous ones. They charged £10 P&P. If that's still the case I reckon that'd help cover a lot of the costs. I know from personal experience, the urge to see the scientific improvements is important regardless of the improvements you experience. That will cost you to see. They also get a decent slice if the products are bought through the STC site,which 82% do. All looking good. Getting the name out there is massively important.

Look out for us in this week's OK! Magazine ?? We are thrilled to be part of a feature discussing the trend of personalisation in the beauty industry. We have free kits to giveaway for
@OK_Magazine
readers so be sure to pick up a copy!
@TFAcomms
#KnowYourSkin
https://twitter.com/skintrustclub/status/1513903637290004480?s=20&t=TrzwNyL-j6UPtDoZpDFf8Q

All bar one References are Microtox.
THE FISHERIES BLOG
How toxic is the water: using biology to determine water toxicity
Posted by DKSACKETT on APRIL 11, 2022

https://thefisheriesblog.com/2022/04/11/how-toxic-is-the-water-using-biology-to-determine-water-toxicity/

I remember a warning of legal action being put on the MW site. It read something like," We are the only company that produces genuine Microtox reagents. Legal steps will be take for any company claiming to do so." Think it was to put the wind up Alan. As is the norm, Aqua Science probably fired Gwoods for being unprofessional.

And now we'll see it go from 13-90 whilst I continue to post dribble.

Yawn, when will folks see where this is going.
There are many revenue streams across @DeepVerge Group. No single entity/country can slow the triple digit percentage growth similar to last 3 years. Revenues this year, build on recurring revenue from framework agreements, monitoring and consumables from last 2 years #DVRG
https://twitter.com/gjbrandon/status/1512814721493254147?s=20&t=_k2XND2AP2q5rT5kgP2K-w

nd investments. We believe that, with an increase in the number of aptamer-based therapies being developed and subsequent advancement of therapies across various stages of clinical trials, and their eventual commercialization, the opportunities for custom / contract service providers is likely to increase in the foreseen future.

Overall, aptamer therapeutics, technologies and services market is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Companies Mentioned

Big list but Deepverge is on it.

https://www.businesswire.com/news/home/20220408005357/en/Global-Aptamers-Therapeutics-Technologies-and-Services-Market-2022-to-2035---Industry-Trends-and-Forecasts---ResearchAndMarkets.com
This report features an extensive study of the current market landscape and the likely future potential associated with the aptamer-based therapies, technologies and services market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.

Post the approval of the first aptamer-based therapy, Macugen, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential of aptamers as theranostic agents. In the following year, the outstanding annual sales (USD 200 million) of the aforementioned product further bolstered the confidence of industry stakeholders in this new therapeutic modality, creating lucrative opportunity for therapy developers. Further, over 100 clinical trials, along with several preclinical studies, have demonstrated the potential of aptamers as a safe and effective treatment modality, owing to their unique characteristics, such as high binding affinity and specificity.

Given the various advantages, aptamer-based therapeutics in the current pipeline are targeting a range of therapeutic areas, such as oncological disorders, ophthalmological disorders and metabolomic disorders. It is worth mentioning that, in order to further enhance their performance, aptamers can be linked with various diagnostic agents, using physical or chemical conjugation.

Moreover, to ensure the development of more effective therapy candidates, several players have developed novel aptamer-based technologies that can be used for research, drug delivery and diagnostic applications. At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment.

In addition, post the onset of COVID-19 pandemic, there has been a significant rise in the demand for COVID-19 testing kits, which has prompted several companies to develop aptamer-based diagnostic tools for the detection of SARS-CoV-2. Consequently, to support the various initiatives undertaken by industry players, investments worth over USD 1.3 billion have been reported in the past five years.

Presently, a significant portion of the existing manufacturing capabilities and expertise in this domain belongs to more than 50 contract service providers. Therefore, several researchers and therapy / diagnostic developers prefer to outsource their aptamer manufacturing operations.

Given the rise in global disease burden over the past few years, there has been an evident increase in the demand for effective targeted therapies along with novel diagnostic approaches to reduce development timelines cont'

A millionaire? Thanks Gwoods x

Gwoods, It's app based trades from the likes of eToro/212, who charge no commission but you receive poor quotes on the ask and bid. Usually used by kids having a gamble with their pocket money. Don't give up. you'll get something right sooner or later

I did not find the article. What I did find is a way to read it without us having to pay the £200 subscription fee.